June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Aqueous Vascular Endothelial Growth Factor and Ranibizumab Concentrations after Monthly and Bimonthly Intravitreal Injections of Ranibizumab for Age-Related Macular Degeneration
Xiying Wang; Tomoko Sawada; Masashi Kakinoki; Taichiro Miyake; Hajime Kawamura; Yoshitsugu Saishin; Ping Liu; Masahito Ohji
Author Affiliations & Notes
  • Xiying Wang
    Ophthalmology Department., Shiga University of Medical Science, Otsu, Japan
    Ophthalmology, Eye Hospital, First Affiliated Hospital,,Harbin Medical University, Harbin, China
  • Tomoko Sawada
    Ophthalmology Department., Shiga University of Medical Science, Otsu, Japan
  • Masashi Kakinoki
    Ophthalmology Department., Shiga University of Medical Science, Otsu, Japan
  • Taichiro Miyake
    Ophthalmology, Kohka Public Hospital, Kohka, Japan
  • Hajime Kawamura
    Ophthalmology Department., Shiga University of Medical Science, Otsu, Japan
  • Yoshitsugu Saishin
    Ophthalmology Department., Shiga University of Medical Science, Otsu, Japan
  • Ping Liu
    Ophthalmology, Eye Hospital, First Affiliated Hospital,,Harbin Medical University, Harbin, China
  • Masahito Ohji
    Ophthalmology Department., Shiga University of Medical Science, Otsu, Japan
  • Footnotes
    Commercial Relationships Xiying Wang, None; Tomoko Sawada, None; Masashi Kakinoki, None; Taichiro Miyake, None; Hajime Kawamura, None; Yoshitsugu Saishin, None; Ping Liu, None; Masahito Ohji, Alcon (F), Novartis (F), Novarits (C), Pfizer (C), Santen (F), Santen (C), Shionogi (C), Carl Zeiss (C), Bayer (C), Senju (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 3169. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Aqueous Vascular Endothelial Growth Factor and Ranibizumab Concentrations after Monthly and Bimonthly Intravitreal Injections of Ranibizumab for Age-Related Macular Degeneration
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Xiying Wang, Tomoko Sawada, Masashi Kakinoki, Taichiro Miyake, Hajime Kawamura, Yoshitsugu Saishin, Ping Liu, Masahito Ohji; Aqueous Vascular Endothelial Growth Factor and Ranibizumab Concentrations after Monthly and Bimonthly Intravitreal Injections of Ranibizumab for Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2013;54(15):3169. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: To evaluate vascular endothelial growth factor (VEGF) and ranibizumab concentrations in eyes with age-related macular degeneration (AMD) after monthly and bimonthly intravitreal ranibizumab injections.

Methods: Aqueous humor samples were obtained from 19 eyes before and after treatment. Nine eyes received three monthly injections and 10 eyes received two bimonthly injections. The lower detectable limits of the VEGF and ranibizumab concentrations were 9.0 pg/ml and 0.156 ng/ml, respectively, measured by enzyme-linked immunosorbent assay.

Results: The aqueous VEGF concentrations with monthly injections decreased below the lower detectable limit in eight eyes at month 1 and seven eyes at month 2 from the mean baseline level of 94.7±32.0 pg/ml; with bimonthly injections, the concentrations decreased below the lower detectable limit in four eyes from the mean baseline level of 129.3±53.0 pg/ml at month 2. The aqueous VEGF concentrations with both regimens decreased significantly at month 2 (P<0.001, P<0.01, respectively). The mean aqueous ranibizumab concentrations with monthly injections were 71.2±48.6 ng/ml at month 1 and 96.3±65.4 ng/ml at month 2. The mean aqueous ranibizumab concentrations with bimonthly injections was 11.0 ± 27.1 ng/ml in eight eyes and decreased below the lower detectable limit in one eye at month 2.

Conclusions: The aqueous VEGF concentration was suppressed for 2 months after the initial intravitreal ranibizumab injection in some eyes with AMD. The aqueous ranibizumab concentration in these eyes may remain sufficiently high to suppress VEGF in some eyes 2 months after the initial injection.

Keywords: 412 age-related macular degeneration • 427 aqueous • 748 vascular endothelial growth factor  
© 2013, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2015 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept